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INTRODUCTION {#gcc22277-sec-0001}
============

Chronic lymphocytic leukemia (CLL) is molecularly and clinically very heterogeneous: some patients have stable disease for many years whereas others show a rapidly progressive course requiring early treatment (Swerdlow et al., [2008](#gcc22277-bib-0056){ref-type="ref"}; Zenz et al., [2010](#gcc22277-bib-0060){ref-type="ref"}). Although new targeted therapeutic approaches (i.e., small molecule kinase and BCL2 inhibitors) are improving the outcome, there remains no curative option besides allogeneic stem cell transplantation.

Approximately 80% of CLL cases show genetic alterations at diagnosis, mainly copy number alterations (CNA) rather than chromosomal translocations. The main recurrent CNA are losses of 13q14, 11q22‐q23, and 17p13, and trisomy 12. Currently, as part of routine diagnosis, these four CNAs are tested using fluorescence in situ hybridization (FISH) and based on them, five prognostic groups can be defined (Dohner et al., [2000](#gcc22277-bib-0014){ref-type="ref"}). Deletion in 13q14 is the most frequent CNA in CLL (∼50% of cases) and is associated with good prognosis when it is found as a sole abnormality (Dohner et al., [2000](#gcc22277-bib-0014){ref-type="ref"}). Trisomy 12 is present in 10--20% and is associated with *NOTCH1* mutations (Balatti et al., [2012](#gcc22277-bib-0002){ref-type="ref"}; Lopez et al., [2013](#gcc22277-bib-0030){ref-type="ref"}; Villamor et al., [2013](#gcc22277-bib-0057){ref-type="ref"}). The 11q22‐q23 losses are rarely found in early‐stage disease but are present in ∼25% of patients with advanced disease; the minimal deleted region harbors *ATM*, which is mutated in one‐third of cases (Austen et al., [2005](#gcc22277-bib-0001){ref-type="ref"}), and *BIRC3*, mutated in a small subset of cases (Rossi et al., [2012](#gcc22277-bib-0045){ref-type="ref"}). The presence of 11q losses has been associated with more rapid disease progression and extensive lymphadenopathy as well as with shorter time to first treatment (TTT), duration of remission, and overall survival (Dohner et al., [1997](#gcc22277-bib-0013){ref-type="ref"}). Nevertheless, these associations in the rituximab era are less marked (Hallek et al., [2010](#gcc22277-bib-0024){ref-type="ref"}; Skowronska et al., [2012](#gcc22277-bib-0054){ref-type="ref"}; Rosenquist et al., [2013](#gcc22277-bib-0044){ref-type="ref"}). Finally, 17p13 deletions are found in 4--9% of CLL requiring first‐line therapy; they are found in up to 30--40% patients with relapsed/refractory disease (Zenz et al., [2008](#gcc22277-bib-0058){ref-type="ref"}, [2011](#gcc22277-bib-0061){ref-type="ref"}), mainly due to selection of pre‐existing subclones with mutated *TP53* (Rossi et al., [2014](#gcc22277-bib-0046){ref-type="ref"}). Roughly 80% of cases with 17p deletions show *TP53* mutations (Zenz et al., [2008](#gcc22277-bib-0058){ref-type="ref"}). 17p/*TP53* alterations are associated with worse prognosis and have important clinical implications at the time of starting the treatment given that these cases are highly chemorefractory to standard cytotoxic regimens (Dohner et al., [1995](#gcc22277-bib-0012){ref-type="ref"}; Catovsky et al., [2007](#gcc22277-bib-0008){ref-type="ref"}; Forconi et al., [2008](#gcc22277-bib-0017){ref-type="ref"}; Dicker et al., [2009](#gcc22277-bib-0011){ref-type="ref"}; Zenz et al., [2009](#gcc22277-bib-0059){ref-type="ref"}). Because chemotherapy depends on *TP53* it is mandatory to screen for *TP53* alterations before initiation of treatment and to consider different therapeutic approaches like alemtuzumab, idelalisib, navetoclax, or ibrutinib (Pospisilova et al., [2012](#gcc22277-bib-0040){ref-type="ref"}; Farooqui et al., [2015](#gcc22277-bib-0016){ref-type="ref"}).

Besides 11q and 17p losses, other CNAs reported to confer prognostic value are gains at 2p and 8q and losses at 6q and 8p (Chapiro et al., [2010](#gcc22277-bib-0009){ref-type="ref"}; Gunnarsson et al., [2010](#gcc22277-bib-0020){ref-type="ref"}; Brown et al., [2012](#gcc22277-bib-0006){ref-type="ref"}). Unfortunately, routine FISH testing does not include these regions. Moreover, it has been recently reported that in a series of CLL cases with a normal FISH pattern the presence of CNAs detected by single nucleotide polymorphism (SNP) array (in 22% of cases) was prognostically relevant (Mian et al., [2013](#gcc22277-bib-0032){ref-type="ref"}). The detection of all these genetic biomarkers may be of paramount importance in clinical practice, since they may identify high risk patients and eventually guide the treatment. Microarray studies of CLL patients have also defined a strong association of increased genomic complexity with poor prognosis (Edelmann et al., [2012](#gcc22277-bib-0015){ref-type="ref"}; Malek, [2013](#gcc22277-bib-0031){ref-type="ref"}), represented mainly by cases with a mutated *TP53* gene. Clonal evolution (Gunnarsson et al., [2011](#gcc22277-bib-0021){ref-type="ref"}; Braggio et al., [2012](#gcc22277-bib-0005){ref-type="ref"}; Knight et al., [2012](#gcc22277-bib-0028){ref-type="ref"}; Malek, [2013](#gcc22277-bib-0031){ref-type="ref"}) and chromothripsis (Edelmann et al., [2012](#gcc22277-bib-0015){ref-type="ref"}) have also been associated with shorter survival in CLL. Overall, these data emphasize the advantages of assessing global genomic complexity by arrays. The only types of genetic alteration that arrays are not able to detect are balanced translocations, which are rare in CLL and have not been associated to poor clinical behavior, except if they are accompanied by a 17p loss (Baliakas et al., [2014](#gcc22277-bib-0003){ref-type="ref"}).

Array‐based platforms are now widely used in routine diagnosis, especially for constitutional diseases, and are gaining popularity in assessing cancer samples. Many studies have demonstrated that FISH and arrays have more than 90% concordance and that arrays better define gains and losses (Schwaenen et al., [2004](#gcc22277-bib-0051){ref-type="ref"}; Pfeifer et al., [2007](#gcc22277-bib-0038){ref-type="ref"}; Gunn et al., [2008](#gcc22277-bib-0018){ref-type="ref"}; Sargent et al., [2009](#gcc22277-bib-0049){ref-type="ref"}; Kay et al., [2010](#gcc22277-bib-0027){ref-type="ref"}; O\'Malley et al., [2011](#gcc22277-bib-0035){ref-type="ref"}; Ouillette et al., [2011](#gcc22277-bib-0036){ref-type="ref"}; Rinaldi et al., [2011](#gcc22277-bib-0043){ref-type="ref"}; Edelmann et al., [2012](#gcc22277-bib-0015){ref-type="ref"}; Knight et al., [2012](#gcc22277-bib-0028){ref-type="ref"}). The few discordances observed in these studies are usually due to insufficient probe density and subclonality. Another advantage of arrays versus FISH is that only arrays are able to detect copy‐number neutral loss of heterozygosity (CNN‐LOH) of mutated *TP53*, for instance (Ouillette et al., [2011](#gcc22277-bib-0036){ref-type="ref"}), and also 11q losses not targeting *ATM*, gains of chromosome 12 not involving the centromere, and 13q losses not targeting *DLEU2*, which are the standard FISH probes used in CLL samples (Gunn et al., [2009](#gcc22277-bib-0019){ref-type="ref"}; Hagenkord et al., [2010](#gcc22277-bib-0022){ref-type="ref"}).

In the present study, we describe the development of a custom array for CLL that interrogates the most significant genetic alterations, is particularly enriched in CLL‐associated regions, and that captures the complex patterns of aberrations, including chromothripsis. This tool may guide the risk‐stratification and therapeutic decisions according to the genomic alterations or genomic complexity of each patient.

MATERIALS AND METHODS {#gcc22277-sec-0002}
=====================

Patients {#gcc22277-sec-0003}
--------

The study included 133 patients from the Hospital Clinic (Barcelona) with the diagnosis of CLL according to the WHO criteria (Swerdlow et al., [2008](#gcc22277-bib-0056){ref-type="ref"}) (Table [1](#gcc22277-tbl-0001){ref-type="table-wrap"}). All patients gave informed consent in agreement with the Institutional Review Board and according to the International Cancer Genome Consortium guidelines (Hudson et al., [2010](#gcc22277-bib-0026){ref-type="ref"}). In addition, a second series of 47 CLL patients from another institution (University of Leicester, UK, with genetic analyses performed at the University of Kiel) was studied. Fifty‐seven cases (32%) were sampled at the time of diagnosis and the remaining were obtained 7--696 months after diagnosis, with a median of 177 months. Overall, patients were predominantly males (64%), with a median age of 62 years, and most of them presented with Binet stage A (72%). Adverse prognostic factors were detected in about half of the patients: *IGHV* unmutated status in 62% and positive expression of CD38 and ZAP‐70 in 38 and 44% of cases, respectively. At 10 years of follow‐up, 83% patients (95% confidence interval \[CI\]: 71--95%) had received CLL‐specific treatment, and the overall survival (OS) of the entire cohort was 39% (95% CI: 27--51%). Number of cases and techniques applied to each of the series are detailed in Supporting Information Figure S1.

###### 

Main Clinical Characteristics and Outcome of 180 CLL Patients

  Patient characteristics              *N*      \%
  ------------------------------------ -------- ---------------
  Age, years                                    
  Median                               62       
  Range                                33--98   
  Gender                                        
  Male                                 115      64
  Female                               65       36
  Binet stage                                   
  A                                    130      72
  B                                    37       21
  C                                    12       7
  ZAP 70 expression                             
  Negative (≤20%)                      60       56
  Positive (\>20%)                     48       44
  CD38 expression                               
  Negative (≤30%)                      93       62
  Positive (\>30%)                     58       38
  *IGHV* mutational status                      
  Mutated                              59       38
  Unmutated                            96       62
  Mutations                                     
  * NOTCH1*                            26       22
  * SF3B1*                             13       12
  * TP53*                              18       14
  Treated patients                     133      74
  Deceased patients                    83       47
  Patients treated at 10 yr (95% CI)   --       83% (71--95%)
  Overall survival at 10 yr (95% CI)   --       39% (27--51%)

CI, confidence interval; yr, years.

Molecular and Cytogenetic Analyses {#gcc22277-sec-0004}
----------------------------------

DNA was extracted from mononuclear blood cells from CLL patients by using a Qiagen kit (Qiagen, Valencia, CA). All cases had more than 50% tumor cells. *IGHV, TP53, NOTCH1*, and *SF3B1* mutation analyses were performed using direct Sanger sequencing as previously described (Quesada et al., [2012](#gcc22277-bib-0041){ref-type="ref"}; Villamor et al., [2013](http://2013); Delgado et al., [2014](#gcc22277-bib-0010){ref-type="ref"}). Conventional cytogenetics (CC) was performed on G and/or R banded chromosomes obtained after short term culture (usually up to 72 h) without stimulation or with stimulation with e.g. Phorbol 12‐Myristate 13‐Acetate or DSP30 (Shi et al., [2013](#gcc22277-bib-0053){ref-type="ref"}). Results were described according to the International System for Human Cytogenetic Nomenclature (Shaffer et al., [2013](#gcc22277-bib-0052){ref-type="ref"}). Only cytogenetic data from samples obtained within 6 months from the DNA sampling date were considered. The FISH panel used interrogated the commonly deleted regions in 11q22, 13q14.3, and 17p13 as well as (partial) trisomy 12 (Abbott Molecular, Des Plaines, IL). For the detection of chromosomal aberrations affecting the *TERT* locus, FISH was applied using a three color break‐apart assay (RP11‐678B2 spectrum green, RP11‐117B23 diethylaminocoumarin, and RP11‐356C5 spectrum orange) (Nagel et al., [2010](#gcc22277-bib-0034){ref-type="ref"}). At least one hundred nuclei were examined for each probe and were evaluated in accordance with the diagnostic cut‐offs of the respective laboratories.

Copy Number Arrays {#gcc22277-sec-0005}
------------------

A custom oligonucleotide‐based comparative genomic hybridization (CGH) array was designed based on SurePrint G3 Human CGH 8x60K microarray using eArray software (Agilent Technologies, Palo Alto, CA) (Table [2](#gcc22277-tbl-0002){ref-type="table-wrap"} and Supporting Information Table S1). In the version v1.0 of the array the selected oligonucleotide probes targeted some focal genomic regions at high coverage (7.7--8.4 probes per Kb), some commonly altered regions at medium/high coverage (0.4--1.8 probes per Kb), and the whole genome at a lower coverage (backbone). With this design, the backbone was composed of an average of one probe every 115 kb outside the regions of interest. The probe density was higher in 13q14.3, 11q22‐q23, and 17p13 (Fig. [1](#gcc22277-fig-0001){ref-type="fig"}A) and even more enriched in specific genes related to lymphoid neoplasms (*MTAP*/*CDKN2A/CDKN2B, BCL2L11, BCL11A, REL, BCL2, MALT1, MYC, NMYC*, and *SP110/SP140/SP100*); medium coverage was applied to relatively large regions spanning 6q14.1‐q22.31, 7q31.33‐q33, and 11q22.3‐q23.3. The array was also enriched in probes covering two immunoglobulin loci (*IGH* at 14q32 and *IGK* at 2p11) for B‐cell clonality control. All catalogued germline copy number variants were removed (Database of Genomic Variants: <http://dgv.tcag.ca/dgv/app/home>). The series of 133 patients (and one sequential sample from case 102) from Barcelona (Spain) were hybridized with the version 1.0 outsourced to qGenomics ([www.qgenomics.com](http://www.qgenomics.com)). Then we designed version v3.0, which included three new focal CNA (2q13, 3p21.31, and 10q24.32) and 10340 SNP probes from the Agilent catalog for LOH detection. Regions of potential CNN‐LOH 6q, 8p, 11q, 13q, and 17p were interrogated with 23% (2384) of this set of SNP probes, whereas a backbone of the genome was covered with the remaining probes (7962) (Table [3](#gcc22277-tbl-0003){ref-type="table-wrap"}). The series of 47 CLL patients from Leicester (UK) was hybridized with the v3.0 design outsourced to qGenomics.

![Whole‐genome overview of copy number alterations detected by qChip®Hemo array. (A) Chromosomal view of four altered regions highlighted with a red box. Probes for losses of 13q, 17p, 6q, and 11q14‐q23 are enriched in the array. Gray dots represent individual probes and the higher density of probes in these regions as compared with the backbone coverage can be observed. (B) Frequency plot of copy number alterations in 180 CLL patients. On the X‐axis the chromosomes are represented horizontally, on the Y‐axis the percentage of cases showing the copy number alterations (gains in blue, losses in red).](GCC-54-668-g001){#gcc22277-fig-0001}

###### 

Chromosomal Regions Enriched in the qChip®Hemo Array (GRCh37/hg19) for Detection of Copy Number Alterations

  Chr                                            Start       End         Size       Region (genes)                                                                     Density[a](#gcc22277-note-0002){ref-type="fn"}
  ---------------------------------------------- ----------- ----------- ---------- ---------------------------------------------------------------------------------- ------------------------------------------------
  chr2                                           60676446    60782012    105566     2p16.1 *(BLC11A)*                                                                  Very high
  chr2                                           61104447    61151158    46711      2p16.1 *(REL)*                                                                     Very high
  chr2                                           111878490   111926022   47533      2q13 (*BCL2L11*)                                                                   Very high
  chr2                                           231090445   231223847   133402     2q37.1 *(SP140)*                                                                   Very high
  chr8                                           128747629   128753930   6301       8q24.21 *(MYC)*                                                                    Very high
  chr11                                          108082602   108252729   170127     11q22.3 (*ATM)*                                                                    Very high
  chr13                                          50556688    50699677    142989     13q14.2 (*DLEU2, DLEU1, MIR16‐1, MIR15A*)                                          Very high
  chr17                                          7563917     7591659     27742      17p13.1 (*TP53)*                                                                   Very high
  chr2                                           16050000    16150000    100000     2p24.3 (*MYCN)*                                                                    High
  chr2                                           60500000    61500000    1000000    2p16.1‐p15 (*BCL11A, PAPOLG, REL PUS10, PEX13)*                                    High
  chr2[b](#gcc22277-note-0003){ref-type="fn"}    111376353   111977326   600973     2q13 (*BUB1, ACOXL, BCL2L11*)                                                      High
  chr2                                           230055752   231666905   1611153    2q36.3‐q37.1 (*DNER, TRIP12, FBXO36, SLC16A14, SP110, SP140, SP100*)               High
  chr2                                           89118885    89438885    320000     2p11.2 (*IGK)*                                                                     High
  chr3[b](#gcc22277-note-0003){ref-type="fn"}    46996537    48502973    1506436    3p21.31 (*SETD2,MAP4, CDC25A, FBXW12*)                                             High
  chr9                                           21798721    22125806    327085     9p21.3 *(MTAP, CDKN2A, CDKN2B)*                                                    High
  chr10[b](#gcc22277-note-0003){ref-type="fn"}   103818600   104498019   679419     10q24.32 (*GBF1, NFKB2, PSD, FBXL5, SUFU*)                                         High
  chr13                                          48007849    54010887    6003038    13q14.2‐q14.3                                                                      High
  chr14                                          106328955   106808955   480000     14q32.33 (*IGH)*                                                                   High
  chr17                                          6500001     10700000    4199999    17p13.1                                                                            High
  chr18                                          56250406    61070906    4820500    18q21.32‐q21.33 (*MALT1, ZNF532, SEC11C, PIGN, TNFRSF11A, ZCCHC2, PHLPP1, BCL2)*   High
  chr6                                           78000000    120000000   42000000   6q14.1‐q22.31                                                                      Intermediate
  chr7                                           124449746   136150979   11701233   7q31.33‐q33                                                                        Intermediate
  chr11                                          106000000   118000000   12000000   11q22.3‐q23.3                                                                      Intermediate

Very high coverage: 7.7--8.4 probes x Kb; high: 0.7--1.8 probes x Kb; intermediate: 0.1--0.2 probes x Kb.

Regions added to v3.0 and not enriched in v1.0.

###### 

Chromosomal Regions Enriched in the qChip®Hemo Array v3.0 (GRCh37/hg19) for Detection of Copy Number Neutral Loss of Heterozigosity

  Chr        Start       End         Size    Region           No. SNP probes   Density (probe/Mb)
  ---------- ----------- ----------- ------- ---------------- ---------------- --------------------
  chr6       76070412    149814761   73744   6q14‐q25.1       1046             14
  chr8       285123      28752104    28467   8p23.3‐p21.1     662              23
  chr11      103864934   119876696   16012   11q22.3‐q23.3    252              16
  chr13      44049120    59049915    15001   13q14.11‐q21.1   185              12
  chr17      72082       16177386    16105   17p13.3‐p11.2    238              15
  Backbone   --          --          --      whole‐genome     7962             3

For each hybridization 300--600 ng of DNA were used. Array hybridization and scanning procedures were performed as previously described (Salaverria et al., [2013](#gcc22277-bib-0048){ref-type="ref"}). As quality control metric we used DLR spread (probe‐to‐probe log ratio noise of an array) and all samples had low values (mean 0.17; range 0.106--0.35) indicating high quality of hybridization. The qChip®Hemo array data have been deposited to GEO under the accession GSE66923.

A subset of 34 samples was additionally analyzed using Affymetrix Genome‐Wide Human SNP6.0 microarrays (SNP6.0) (Affymetrix, Santa Clara, CA), outsourced to Centro Nacional de Genotipado CEGEN ([www.cegen.org](http://www.cegen.org) *)* following the manufacturer\'s procedures as previously described (Royo et al., [2012](#gcc22277-bib-0047){ref-type="ref"}). Nexus 7.5 Discovery Edition (Biodiscovery, El Segundo, CA) was used for global analysis and visualization of results from both platforms. Array data were visually inspected for possible subclonal alterations. Coordinates are given according to the GRCh37/hg19 assembly.

Statistical Methods {#gcc22277-sec-0006}
-------------------

To correlate data from qChip®Hemo, FISH, and karyotyping crosstab analysis (Fisher\'s exact test) and Cohen\'s kappa coefficient were used to measure the agreement between the techniques for four categorical variables (11q, 13q, and 17p losses and trisomy 12). TTT was calculated from the date of sampling to the date of frontline treatment or last follow‐up, and OS was calculated from the date of sampling to the date of death or last follow‐up. TTT and OS were plotted using the Kaplan--Meier method and the log‐rank test was applied. Multivariate analysis was performed with the stepwise proportional hazards model (Cox model) assessing that the covariates used in the model did not violate the proportional hazard assumption. The 37 cases with post‐treatment samples were excluded from the survival analyses. PASW Statistics 18.0 (SPSS, Hong Kong S.A.R) was used. All statistical tests were two‐sided and the level of statistical significance was set at 0.05.

RESULTS {#gcc22277-sec-0007}
=======

Landscape of Alterations and Complexity of CLL Genomes Detected by a qChip®Hemo Array {#gcc22277-sec-0008}
-------------------------------------------------------------------------------------

Of the 180 cases hybridized with qChip®Hemo, 154 (86%) had CNA. In total, 511 alterations were identified (mean 2.8 CNAs per sample; range 0--28), 377 being deletions and 134 gains (Fig. [1](#gcc22277-fig-0001){ref-type="fig"}B and Supporting Information Table S2). Recurrent alterations usually tested in CLL were identified in 143 cases (79%): loss in 13q14.3 (48%), loss in 11q22‐q23, including the *ATM* gene (24%), loss in 17p13, including the *TP53* gene (12%), and trisomy 12 (21%). Interestingly, 35 of the 43 (81%) cases with loss of 11q included also the *BIRC3* gene, and an additional case showed only deletion of *BIRC3* but no loss of *ATM* (case 184). The qChip®Hemo detected homozygous deletions of 13q14.3 in 22 (25%) of the samples with this alteration (Supporting Information Figs. S2A and S2B). Besides 13q14.3, a single homozygous deletion was found (D961, 11q23.2‐q23.3, size 1.6 Mb and telomeric to the *ATM* gene) and only one case (D1016) showed amplifications (three discontinuous amplifications in 12p13.3, 12p12.3, and 12p12.1). Other recurrent CNAs were losses of 6q (7%), gains of 2p (6%), focal loss of 3p21 (5%), and 4p losses, 8p losses, and 8q gains (4% each). Among the 47 cases hybridized qChip®Hemo v3.0 (including SNP probes) only two cases showed copy CNN‐LOH of 11q, no other CNN‐LOH was detected in 6q, 8p, 13q, or 17p.

From patient 102, two sequential samples were studied: at diagnosis and at clinical progression 4 years later. The case showed no CNAs at diagnosis but a complex genetic profile with 17 alterations at progression, including 17p loss (Supporting Information Fig. S3).

Of note, using qChip®Hemo array analysis we identified eight cases (8/180; 4%) with multiple lesions in single chromosomes, a pattern suggestive of chromothripsis (at least seven switches between two or more copy number states detected on an individual chromosome) (Edelmann et al., [2012](#gcc22277-bib-0015){ref-type="ref"}; Rausch et al., [2012](#gcc22277-bib-0042){ref-type="ref"}). Six of the cases had a deletion in 17p, with concomitant mutation of *TP53* in three of these. Interestingly, in three of the eight cases with the chromothripsis‐like pattern we observed a shattered 5p arm characterized by alternating losses and gains, including gain of the *TERT* (Figs. [2](#gcc22277-fig-0002){ref-type="fig"}A and [2](#gcc22277-fig-0002){ref-type="fig"}B). To confirm the alterations at the *TERT* locus we performed FISH with a three color break‐apart assay (Nagel et al., [2010](#gcc22277-bib-0034){ref-type="ref"}). Consistent with the array results, one case had a gain of the *TERT* locus in 30% of the nuclei analyzed (D1016). The other two cases (D1089 and 094) showed gain of the *TERT* locus in 86% and 62% of the nuclei, respectively, and loss of the centromeric region with breakpoints closely centromeric of *TERT*. Interestingly, gain of *TERT* in case 094 showed a tandem duplication pattern (Fig. [2](#gcc22277-fig-0002){ref-type="fig"}C). Two cases without 5p alterations showed a normal FISH pattern, i.e. two normal copies of the gene (D961 and D990).

![Chromothripsis of chromosome 5 detected by qChip®Hemo array and *TERT* analysis. (A) An overview of whole‐genome alterations of 3 CLL patients with chromothripsis is shown in the upper panel. Chromosomes 1 to 22 are represented horizontally (gains in blue, losses in red). (B) Chromosome 5 of the three affected patients; 5p was involved by chromothripsis in all cases and extended to 5q in one patient. The *TERT* gene, included in the minimaly gained region, is highlighted by a square. All cases showed concomitantly gain of 17q and loss of 17p (with mutation of *TP53* only in case D1016). (C) Interphase FISH analysis confirmed gain of *TERT* in the three cases with gain. FISH results of case D1016 showed three signals for RP11‐678B2 (green), RP11‐117B23 (blue), and RP11‐356C5 (orange); FISH results of case D1089 and 094 showed three signals for RP11‐678B2 (green) and RP11‐117B23 (blue) and one signal for RP11‐365C5 (orange), and case 094 showed an amplification or tandem duplication pattern. Arrows indicate *TERT* signals.](GCC-54-668-g002){#gcc22277-fig-0002}

Comparison of the Custom Array with FISH, Metaphase Cytogenetics, and SNP6.0 Array {#gcc22277-sec-0009}
----------------------------------------------------------------------------------

We next compared alterations detected by qChip®Hemo array and FISH in 106 cases. The median percentage and range of altered cells by FISH was 81% (range 20--99) for 11q loss, 62% (range 20--90) for trisomy 12, 62% (range 10--100) for 13q loss, and 30% (range 10--100) for 17p (Supporting Information Tables S3 and S4). Concordance measured by kappa coefficient showed perfect agreement for loss of 11q and trisomy 12 (*κ* = 1.00), strong for 13q loss (*κ* = 0.806), and moderate for 17p loss (*κ* = 0.598). Overall, there was a high specificity (100% for all regions tested) and sensitivity (mean: 84%; 100% for 11q loss and trisomy 12, 84% for 13q loss, and 50% for 17p loss). All discrepancies corresponded to subclonal alterations detected only by FISH in 10--22% of the cells in 10 cases with 13q14 FISH deletion and 10--17% of the cells in 13 cases with 17p FISH deletion. Among the 26 cases without CNAs by array, four cases had only deletion of 13q14 by FISH in 12, 12, 14, and 22% of the cells, respectively.

Comparison between the qChip®Hemo array and CC results was performed using only data from the 64 cases with abnormal karyotypes (Supporting Information Tables S3 and S5 and Fig. S4). The concordance was strong for 11q loss and trisomy 12 (*κ* = 0.806 and 0.779) and good for 17p loss (*κ* = 0.706). Thirteen of the 15 (87%) discrepancies were CNAs detected by array but not by CC (five deletions of 11q, 5 trisomies 12, and 3 deletions of 17p). In two cases, the 17p deletions were not detected by array. Deletion in 13q was observed in 18 cases by CC, 14 of them were also detected by array but four subclonal deletions were only detected by CC (in 2, 3, 4, and 6 metaphases, respectively).

The combination of CC and the qChip®Hemo array information identified that common losses in 13q and 17p were associated with recurrent translocations involving these regions: nine translocations involving 13q with chromosomes 3, 7, 9, 11, 14, 16, and 17 as partners had loss of the minimal region in 13q14.3 in all cases except two. Similarly, nine translocations involving chromosome 17 with chromosomes 4, 5, 13, 15, and 18 as partners resulted in *TP53* loss in all cases except two. Interestingly, 3 cases had translocations involving 3p, and one of them (case D1024) had a focal loss of 2.7 Mb, including the *SETD2* and *MAP4* genes, due to an unbalanced translocation with 13q14, *t*(3;13)(p22;q14). Interestingly, a *MALT1*‐*MAP4* fusion has been reported in diffuse large B‐cell lymphoma (Murga Penas et al., [2006](#gcc22277-bib-0033){ref-type="ref"}). No translocations of 11q were found, although it was the second most frequently lost region. Three cases harbored the *t*(14;18)(q32;q21) but no losses were observed in the 18q region.

The results of the qChip®Hemo array were next compared with the SNP6.0 array results in 34 cases. Both platforms reliably detected the same CNAs (Supporting Information Fig. S5), and only two minor discrepancies were observed: a biallelic loss in 13q14.3 that was detected as a monoallelic loss by SNP6.0 (Supporting Information Fig. S2C) and a small and subclonal loss in 13q14.2 (35 Kb) in case 038 detected only by qChip®Hemo (due to a high coverage of the region in the targeted array: 326 probes in qChip®Hemo and 12 probes in SNP6.0).

Gene Mutations {#gcc22277-sec-0010}
--------------

High risk mutations in *NOTCH1*, *SF3B1*, and *TP53* were detected in 22, 12, and 14% of the patients, respectively. In relation of common CNAs, trisomy 12 was more common in cases with *NOTCH1* mutations than in cases with *NOTCH1* wild‐type (*P =* 0.01); 13q14 losses were more frequent in cases with wild‐type *NOTCH1* compared with those with *NOTCH1* mutations (*P* = 0.015); and 17p loss was associated with *TP53* mutations (*P* \< 0.001) (Supporting Information Fig. S6). Of the 26 cases without CNAs by array eight had mutations in *NOTCH1* and four had *SF3B1* mutations; none had *TP53* mutations.

Clinical Impact {#gcc22277-sec-0011}
---------------

We next investigated whether the presence of CNA detected by qChip®Hemo array had a significant impact on patient outcome. CLL patients with 11q losses had significantly shorter TTT (*P =* 0.003; hazard ratio \[HR\] 2.4; 95% confidence interval \[CI\] 1.3--4.3); patients with two or more CNAs also had shorter TTT (*P =* 0.001; HR 2.6; 95% CI 1.5--4.4) (Supporting Information Fig. S7). Moreover, outcome analysis showed that patients with 17p deletions detected by array analysis had a significantly shorter survival than patients without 17p loss (5‐year OS, 19% versus 60%, *P \<* 0.001). However, patients with 17p loss detected only by FISH in low percentage of cells (\<17%) behaved similarly to patients without 17p loss (Figs. [3](#gcc22277-fig-0003){ref-type="fig"}A and [3](#gcc22277-fig-0003){ref-type="fig"}B). Additionally, patients with chromothripsis‐like patterns had poor prognosis compared with patients without such a pattern (5‐year OS 0% versus 56%; *P =* 0.02) (Fig. [3](#gcc22277-fig-0003){ref-type="fig"}C). Finally, stratification of patients according to number of CNAs showed that chromosomal complexity correlated with prognosis (\>6 CNAs vs. 4--6 CNAs vs. 0--3 CNAs; 5‐year OS 19, 45, and 61%, respectively; *P =* 0.001) (Fig. [3](#gcc22277-fig-0003){ref-type="fig"}D). In a multivariate analyses assessing OS (including 17p13 deletions, presence of chromothripsis, and genomic complexity \[\>6 CNAs\]), only deletions of 17p13 (HR 3.5; 95% CI: 1.7--7.2; *P* = 0.001) showed independent prognostic impact. CNA in CLL patients analyzed by qChip®Hemo array could recapitulate the genetic model of CLL originally developed by Dohner et al., [2000](#gcc22277-bib-0014){ref-type="ref"} based on FISH results (*P* \< 0.001) with increasing survival times according to five genetic categories (17p loss, 11q loss, trisomy 12, no alterations, and 13q loss) (Supporting Information Fig. S8).

![Overall survival (OS) analysis of CLL patients using the qChip®Hemo array. (A) Patients with 17p loss had a significantly shorter OS compared with patients without the 17p deletion. (B) Patients with 17p deletion detected by array had shorter OS compared with patients with 17p deletion detected only by FISH (10--17% cells in all cases), and patients without 17p deletion. (C) Patients with chromothripsis show significantly shorter OS compared with cases without. (D) Kaplan--Meier plot of OS of CLL patients according to increasing number of CNAs (0--3, vs. 4--6 vs. \>6 alterations). (\**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001). CT, chromothripsis; D, deceased; N, number; WT, wild‐type (not deleted). \[Color figure can be viewed in the online issue, which is available at [wileyonlinelibrary.com](http://wileyonlinelibrary.com).\]](GCC-54-668-g003){#gcc22277-fig-0003}

DISCUSSION {#gcc22277-sec-0012}
==========

During the last decade, FISH has represented a powerful tool to assess the main four genomic alterations in CLL and has also been a very useful technique to predict the patient\'s outcome (Dohner et al., [2000](#gcc22277-bib-0014){ref-type="ref"}). More recently, it has been used to guide therapy in a subset of patients (Hallek et al., [2008](#gcc22277-bib-0023){ref-type="ref"}). Karyotype analysis can identify translocations and high genomic complexity in addition to common chromosomal losses, but has the limitation of the low mitotic rate of the CLL cells in culture. Several recent reports have shown that low and high resolution arrays are able to detect characteristic CLL alterations and to provide additional prognostic information compared with standard FISH using four markers (deletion of 11q, 13q, and 17p, and trisomy 12) (Chapiro et al., [2010](#gcc22277-bib-0009){ref-type="ref"}; Gunnarsson et al., [2010](#gcc22277-bib-0020){ref-type="ref"}, [2011](#gcc22277-bib-0021){ref-type="ref"}; Edelmann et al., [2012](#gcc22277-bib-0015){ref-type="ref"}; Mian et al., [2013](#gcc22277-bib-0032){ref-type="ref"}). Moreover, Mian et al., [2013](#gcc22277-bib-0032){ref-type="ref"} found that large alterations could also further predict the outcome in the substantial subgroup (20%) of CLL patients with a normal FISH for the 11q22‐q23, 13q14, chromosome 12, and 17p13 regions. In addition, several studies show that the presence of genomic complexity in CLL is important for identifying high‐risk patients, which could have been missed or misclassified by using the standard FISH CLL panel alone. In that sense, the array that we have developed has been able to detect the more frequent regions altered in CLL genomes, with expected frequencies as well as other more focal alterations. Moreover, 11q losses and the presence of two or more CNAs detected by the array were related to shorter TTT, whereas 17p loss, increased genomic complexity, and chromothripsis were associated with shorter overall survival. Furthermore, as has been previously reported (Dicker et al., [2009](#gcc22277-bib-0011){ref-type="ref"}; Delgado et al., [2014](#gcc22277-bib-0010){ref-type="ref"}), CLL cases with 17p13 alterations more frequently have complex karyotypes and poor overall survival. Interestingly, in the present study, we demonstrate that patients with 17p loss detected only by FISH in minor subpopulations (\<17%), but not detected by array, behave similarly to patients without 17p loss. This suggests that the lower sensitivity of the array compared to FISH in detecting these small subclones with alteration may not have a direct impact on worse survival.

We here show that qChip®Hemo array data are concordant with FISH and high density array data, and moreover, that this array can detect other alterations (not covered by the FISH panel) with prognostic significance and also complex patterns of alterations in single chromosomes (suggestive of chromothripsis) that cannot be detected by FISH. This phenomenon was detected in eight cases of the present study (4.4% incidence) and was related to poor overall survival. Chromothripsis was initially reported in two CLL cases by whole‐genome sequencing (Campbell et al., [2010](#gcc22277-bib-0007){ref-type="ref"}; Bassaganyas et al., [2013](#gcc22277-bib-0004){ref-type="ref"}) and has been recently reported to identify a subset of CLL patients with worse prognosis (Edelmann et al., [2012](#gcc22277-bib-0015){ref-type="ref"}). Of note, three of the cases with a chromothripsis‐like pattern showed a highly altered 5p arm including gains of *TERT*. This gene at 5p13.33 encodes the telomerase reverse‐transcriptase TERT that is rarely targeted by somatic chromosomal translocations and amplifications in B‐cell neoplasms (Nagel et al., [2010](#gcc22277-bib-0034){ref-type="ref"}). These data and our findings suggest that deregulation of the *TERT* gene by chromosomal abnormalities leading to increased telomerase activity might contribute to B‐cell lymphomagenesis or even to catastrophic chromosomal reorganizations. However, further functional experiments will be needed to address this hypothesis. Noteworthy, alterations in the composition of telomeric proteins (including TERT) have been reported to be involved in the pathogenesis of CLL (Poncet et al., [2008](#gcc22277-bib-0039){ref-type="ref"}). Moreover, susceptibility SNPs in the *TERT* and *POT1* genes, both involved in telomere function, have been described in a large series of CLL patients (Speedy et al., [2014](#gcc22277-bib-0055){ref-type="ref"}).

Previous reports of targeted CN arrays for the analysis of CLL have not been applied in a clinical setting mainly because they did not fully achieve the goal of targeting the main CLL alterations. In 2004 and 2007, the first BAC/PAC array‐CGH CLL platforms for clinical purposes were developed (Schwaenen et al., [2004](#gcc22277-bib-0051){ref-type="ref"}; Patel et al., [2008](#gcc22277-bib-0037){ref-type="ref"}). Despite their low resolution, both platforms showed high sensitivity and specificity compared with FISH. In 2009, a customized Agilent 4\*44K array targeting 15 CLL commonly altered regions was reported (Sargent et al., [2009](#gcc22277-bib-0049){ref-type="ref"}) with an average spacing of 5‐11 kb in CLL regions. Another BAC array was reported in 2011 (Kolquist et al., [2011](#gcc22277-bib-0029){ref-type="ref"}; Schultz et al., [2011](#gcc22277-bib-0050){ref-type="ref"}). However, the major drawback for the clinical utility of this array was the lack of sufficient resolution to identify 13q14.3 and *ATM* losses. Recently, a new CLL customized Agilent 4\*44K has been developed (Houldsworth et al., [2014](#gcc22277-bib-0025){ref-type="ref"}), including 20 regions recurrently showing imbalances in CLL. The application of this platform to a large series of CLL cases revealed that gains of 2p, 3q, and 8q and losses of 8p have prognostic significance. However, this array has not been compared with FISH data.

The qChip®Hemo array that we have designed and tested allows an exhaustive study of CNAs in a single experiment requiring only 300--600 ng of tumor DNA, without the need of cell culture, and can analyze, in a single experiment, genome‐wide alterations. The qChip®Hemo array is also a less time‐consuming and subjective technique compared with FISH. Additionally, with the introduction of a set of SNP probes in the latest version of the qChip®Hemo array also CNN‐LOH could be assessed. Finally, the data reported herein support the qChip®Hemo as a cost‐effective tool that could replace FISH in a clinical setting of patients with CLL or other B‐cell neoplasms.

In conclusion, the present platform constitutes a robust, sensitive, and standardized tool based on a microarray that is able to detect recurrent CNAs in CLL and to properly capture their potential clinical impact. The similar overall performance, easier workflow, dramatic reduction of specialized hands‐on time (crucial in cost calculations), and the whole‐genome screening capacity make qChip®Hemo highly applicable for molecular testing of CLL, with the possibility to detect 17p and 11q losses, and also additional alterations with clinical impact (i.e, loss of 6q or 8p, gain of 2p of 8q, presence of high genomic complexity, and chromothripsis). The information provided by the array can be useful in the clinical setting by providing the clinicians objective and rapid information of genomic alterations. Risk‐adapted therapy of CLL cases stratified based on their genomic alterations may be applied, with the option to vary the therapeutic strategy. However, the prognostic impact of new, focal and less frequent alterations, as well as chromothripsis, would require further studies in prospective clinical trials as well as the implementation of information about mutations of driver genes (i.e. *NOTCH1, SF3B1*, and *TP53*) with potential prognostic relevance.
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